在癌症临床试验中治疗中止后患者报告的结果数据的观点
Bellinda L King-Kallimanis1, Melanie Calvert2, David Cella3
1LUNGevity Foundation, Bethesda, MD, USA.
概括
在停止癌症治疗后收集患者报告的结果 (PRO) 数据需要明确的目标. 不合理的PRO数据收集是不道德的,浪费患者的时间和资源.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 健康 结果 研究 研究 结果
背景情况:
- 患者报告结果 (PRO) 数据对于从患者的角度评估癌症治疗至关重要.
- 在停止治疗后 (由于疾病进展或毒性) 收集PRO数据的价值和方法尚未确定.
研究的目的:
- 描述一个虚拟圆桌讨论,重点是治疗停止后的PRO数据收集.
- 该活动由食品和药物管理局的瘤卓越中心和临界路径研究所在2020年共同赞助.
主要方法:
- 一个为期2小时的虚拟圆桌会议召集了16个不同的利益相关者.
- 参与者包括来自学术界,临床实践,患者倡导,监管机构,医疗技术评估/支付人,行业和PRO仪器开发的专家.
主要成果:
- 一个关键的共识是,任何PRO数据收集治疗后停止必须有明确的,明确的目标.
- 这些目标对于确保收集的数据可以有意义地分析和报告至关重要.
结论:
- 在停止治疗后收集PRO数据需要对其有用性的明确理由.
- 没有合理的理由,这种数据收集被认为是不道德的,不必要地负担患者,并浪费资源.
相关概念视频
Clinical Trials
6.9K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
6.9K
Cancer Survival Analysis
397
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
397
Clinical Trials: Overview
3.0K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.0K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
148
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
148
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Pharmacovigilance
903
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
903


